$5.47
0.071.30%
At close: -
$5.47
0.000.00%
After Hours: Jan 31, 4:38 PM EDT
Comments
Loading...
Latest news for Immatics (NASDAQ:IMTX) Stock
Immatics Stock (NASDAQ: IMTX)
Categories: All
Friday, January 03, 2025
Monday, December 16, 2024
Tuesday, November 19, 2024
Friday, October 11, 2024
Thursday, October 10, 2024
- Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Immatics shares are trading lower after the c...
- Immatics Plans $150M Public Offering Of Its O...
- Immatics Filed For Mixed Shelf Offering; Size...
- Immatics Announced Updated Phase 1B Data On A...
Monday, October 07, 2024
Monday, September 16, 2024
Monday, September 09, 2024
Thursday, September 05, 2024
Thursday, August 15, 2024
Tuesday, August 13, 2024
Wednesday, July 31, 2024
Monday, July 22, 2024
Friday, May 24, 2024
Thursday, May 16, 2024
Thursday, March 21, 2024
Monday, March 18, 2024
Thursday, January 18, 2024
Wednesday, January 17, 2024
Wednesday, November 08, 2023
Thursday, November 02, 2023
Tuesday, October 24, 2023
Monday, September 11, 2023
Thursday, August 17, 2023
Thursday, August 10, 2023
Monday, July 24, 2023
Tuesday, June 27, 2023
Thursday, June 22, 2023
Tuesday, June 13, 2023
Tuesday, May 16, 2023
- Recap: Immatics Q1 Earnings
- Immatics Biotechnologies Granted U.S. Patent #11648276: Immunotherapy against neuronal and brain tumors; #11648292: Immunotherapy against several tumors including gastrointestinal and gastric cancer
- Immatics' Cash Position Of €329.8M, With Cash...
- Immatics Q1 EPS $(0.28) Beats $(0.30) Estimat...
Tuesday, May 02, 2023
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- What's Going On With Immatics Shares Today
- US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Immatics shares are trading higher after the ...
- Immatics Reports Interim Clinical Data From O...
- Immatics Reported Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy With ACTengine IMA203 TCR-T Targeting PRAME